Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2008-06-23 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Proposed Issue of Options 1 page ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is a letter addressed to the Australian Stock Exchange regarding the proposed issue of securities in the form of options to a newly appointed board member. It details the number of options, exercise price, expiry, vesting schedule, and conditions including shareholder approval and future filing of Appendix 3B. The content focuses on the announcement of a capital change related to share options rather than a full financial report or other types of filings. The document length is short (1828 characters), and it is clearly an announcement of a proposed securities issue, fitting the category of Share Issue/Capital Change.
2008-06-23 English
Pharmaxis Concludes Special Protocol Assessment with FDA 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 20 June 2008 from Pharmaxis announcing the conclusion of a Special Protocol Assessment (SPA) with the FDA for a Phase 3 clinical trial of Bronchitol. It discusses the trial design, regulatory interactions, and forward-looking statements. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about regulatory and clinical trial progress, not a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and corporate update that does not fit other specific categories like earnings release, capital update, or management report.
2008-06-19 English
Pharmaxis Establishes Named Patient Program for Bronchitol 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing the establishment of a Named Patient Program for the drug Bronchitol by Pharmaxis. It provides details about the program, the drug, and the companies involved, but does not contain any financial data, regulatory filings, or detailed financial reports. It is a corporate announcement related to product access and patient programs rather than a financial or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or corporate news release, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2008-06-16 English
Long-term safety study of Bronchitol completes 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 12 June 2008 from Pharmaxis Ltd announcing the completion of a long-term safety study of their drug Bronchitol. It discusses clinical trial results, future plans for marketing application, and provides company background information. There are no financial statements, regulatory filings, or detailed financial data. The document is a public announcement of clinical trial progress and company plans, typical of a press release or media release. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous announcements that do not fit other categories. The document length is about 5109 characters, which is consistent with a media release rather than a full report. Therefore, the classification is RNS with high confidence.
2008-06-11 English
Change in substantial holding 5 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder (Orbis Investment Management and related entities) in Pharmaxis Ltd. The form includes tables of related bodies corporate and funds managed by the substantial holder. This type of filing is a notification of changes in major shareholding levels, not a financial report or other corporate announcement. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2008-05-26 English
Pharmaxis` Aridol Authorised for Sale in Germany 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Pharmaxis Ltd has received national approval to market its product Aridol in Germany and other European countries. It provides details about the product, its market potential, and company background. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about product approval and market entry, not a financial report, earnings release, or regulatory filing. It is a typical press release or media announcement about a business development.
2008-05-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.